Investors

Since the company was founded, Cellestia has raised $50 million in private equity and won several non-dilutive research grants to build a proprietary R&D platform yielding a rich pipeline of clinical and preclinical programs, which are validating the approach and potential of this new class of therapeutic targets. As a rapidly growing integrated R&D company, having achieved major milestones such as confirmed safety, target engagement and entering phase 2 for the clinical lead, and in vivo proof of concept across multiple indications for the pipeline programs, the company is preparing for further financing rounds.